A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

Study Identifier
MAF-AGN-OPH-DE-016
CT.gov Identifier
NCT02117687
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dry Eye
    • Study Drug
  • carboxymethylcellulose 0.5%/glycerin 0.9%
  • sodium hyaluronate 0.18%
    • Phase
    Phase 4
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Use of artificial tears for dry eye in both eyes for at least 3 months * Use of preservative-free artificial tears at least twice daily for 2 weeks;
    Exclusion Criteria:
    * Cataract, laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK) surgery in the last 12 months * Use of punctal plugs or contact lenses in the last month * Active ocular allergy within last 2 years * Best corrected visual acuity (BCVA) less than 20/200 in either eye

    Protocol Summary

    This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

    Study Locations

    Location
    Status
    Location
    Paris, France
    Status
    Not applicable
    Location
    London, United Kingdom
    Status
    Not applicable